Medicines (Rx) 
The Original Manufacturing Technology of "PG2® Lyo. Injection 500mg" Won the National Innovation Award
2017 . 12 . 18
Used WebPilot
Used Link Reader
PhytoHealth Corporation, a subsidiary of the Maywufa Healthcare Group, has successfully developed and marketed "PG2® Lyo. Injection 500mg". This product is currently the only new prescription drug worldwide for the treatment of Cancer-Related Fatigue (CRF). PhytoHealth has invested significantly in establishing a sterile botanical drug manufacturing facility equipped with innovative equipment and proprietary manufacturing technology. This facility is the first of its kind in Asia to comply with PIC/S GMP standards, and its advanced manufacturing capabilities have earned PhytoHealth the National Innovation Award.
The development of PG2® Lyo. Injection 500mg took PhytoHealth Corporation 12 years, culminating in the successful launch of the first new drug developed by a Taiwanese team, approved by the Taiwan Food and Drug Administration of the Ministry of Health and Welfare. Chen Kuan-Chih, President of Maywufa, explained that PG2® Lyo. Injection 500mg utilizes Astragalus membranaceus, a plant recognized by the International Pharmacopoeia. The production process involves rough extraction, fine extraction, separation, high purification, and the application of advanced lyophilized injection technology. Despite being derived from plant material, PG2® Lyo. Injection 500mg is a compliant new drug prescribed by doctors and can be used in Western medicine treatment. Its efficacy and safety have been confirmed.
Li Cheng-Chia, Chairman of the group, stated that PhytoHealth has meticulously overseen every step, from medicinal raw material sourcing to mass production, successfully establishing a streamlined process of R&D, manufacturing, and marketing. This approach is recognized as a successful operational model for new drug research and development in Taiwan. Since its market launch, PG2® Lyo. Injection 500mg has benefited cancer patients suffering from the side effects of chemotherapy and radiotherapy and has been adopted by more than 30 large hospitals.
The development of PG2® Lyo. Injection 500mg took PhytoHealth Corporation 12 years, culminating in the successful launch of the first new drug developed by a Taiwanese team, approved by the Taiwan Food and Drug Administration of the Ministry of Health and Welfare. Chen Kuan-Chih, President of Maywufa, explained that PG2® Lyo. Injection 500mg utilizes Astragalus membranaceus, a plant recognized by the International Pharmacopoeia. The production process involves rough extraction, fine extraction, separation, high purification, and the application of advanced lyophilized injection technology. Despite being derived from plant material, PG2® Lyo. Injection 500mg is a compliant new drug prescribed by doctors and can be used in Western medicine treatment. Its efficacy and safety have been confirmed.
Li Cheng-Chia, Chairman of the group, stated that PhytoHealth has meticulously overseen every step, from medicinal raw material sourcing to mass production, successfully establishing a streamlined process of R&D, manufacturing, and marketing. This approach is recognized as a successful operational model for new drug research and development in Taiwan. Since its market launch, PG2® Lyo. Injection 500mg has benefited cancer patients suffering from the side effects of chemotherapy and radiotherapy and has been adopted by more than 30 large hospitals.